COMPOSITIONS FOR AFFECTING WEIGHT LOSS

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20150141452A1
SERIAL NO

14602154

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
OREXIGEN THERAPEUTICS INCLA JOLLA CA 92037

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cowley, Michael Alexander Portland, US 15 263
Weber, Eckard San Diego, US 109 2139

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation